ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022
Oral Cancer Prevalence, Mortality, and Costs in Medicaid and Commercial Insurance Claims Data.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 61 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Serum Lipid Profile in Patients With Lip Squamous Cell Carcinoma
Integrating Clinical Psychology Into the Care of Patients With Head and Neck Cancer: A Pilot Randomized Controlled Trial
Who cites it
61 citing papers in PubMed, 8 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Artificial intelligence for oral cancer diagnosis: a systematic review and meta-analysis of image-based and non-imaging models.BMC cancer · 2026Pooled it
- The effectiveness of gender-neutral HPV vaccination programmes in preventing HPV-associated oral cancers: a systematic review.BMC cancer · 2026Pooled it
- C-reactive protein and its ratio with albumin as a marker of poor prognosis in oral cancer: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Pooled it
- Tissue-based genomic instability markers for predicting malignant transformation in oral leukoplakia and proliferative verrucous leukoplakia: a systematic review.Frontiers in oral health · 2026Pooled it
- Socioeconomic factors impacting treatment delays in oral and oropharyngeal squamous cell carcinoma: a systematic review.Cadernos de saude publica · 2025Pooled it
- Polyomaviruses and the risk of oral cancer: a systematic review and meta-analysis.BMC oral health · 2024Pooled it
- Prognostic value of systemic immune-inflammation index and systemic inflammation response index for oral cancers: A systematic review and meta-analysis.Medicina oral, patologia oral y cirugia bucal · 2024Pooled it
- Cytotoxicity of Nanocarrier-Based Drug Delivery in Oral Cancer Therapy: A Systematic Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Expenditures attributable to infant lower respiratory tract infection due to respiratory syncytial virus in the US: A real-world study using the PharMetrics Plus Database, 2015-2023.Human vaccines & immunotherapeutics · 2026Article
- Observational
- Predictors of Lesion Detection in a 12-Year Oral Cancer Screening Program: A Cohort Study in Northern Portugal.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026Article
- Article
- Hospitalized Patients with Oral Cavity Cancer and Ulcerative Mucositis: Implications for Key Cost Drivers and Disparities.Reports (MDPI) · 2026Article
- Quercetin as a multi-targeted therapeutic candidate in oral cancers: molecular mechanisms and preclinical evidence.Molecular biology reports · 2026Review
- Metabolic gene expression-based stratification and prognostic risk predictive model of head and neck squamous cell carcinoma.NPJ systems biology and applications · 2026Article
- Impact of postoperative radiotherapy on combined local SCC events and survival in non-metastatic oral and pharyngeal squamous cell carcinoma.Discover oncology · 2026Article
- Integrated analysis identifies CCNA2 as a candidate diagnostic and prognostic biomarker in oral tongue squamous cell carcinoma.Journal of applied oral science : revista FOB · 2026Article
- AI-assisted image analysis ofBioinformation · 2026Article
- "Enhancing early detection of oral cancer: a comparative study of artificial intelligence models and clinical specialist in lesion classification".BMC cancer · 2025Article
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study compared prevalence, incidence, mortality rates, treatment costs, and risk factors for oral and oropharyngeal cancer (OC/OPC) between two large United States adult cohorts in 2012-2019.
methodsMedicaid and commercial claims data came from the IBM Watson Health MarketScan Database. Logistic regression analyses estimated incidence and risk factors for OC/OPC. Mortality was calculated by merging deceased individuals' files with those of the existing cancer cohort. Summing costs of outpatient and inpatient services determined costs.
resultsPrevalence of OC/OPC in Medicaid enrollees decreased each year (129.8 cases per 100,000 enrollees in 2012 to 88.5 in 2019); commercial enrollees showed a lower, more stable prevalence (64.7 per 100,000 in 2012 and 2019). Incidence trended downward in both cohorts, with higher incidence in the Medicaid (51.4-37.6 cases per 100,000) than the commercial cohort (31.9-31.0 per 100,000). Mortality rates decreased for Medicaid enrollees during 2012-2014 but increased in the commercial cohort. OC/OPC treatment costs were higher for commercial enrollees by $8.6 million during 2016-2019. OC/OPC incidence was higher among adults who were older, male, and white; used tobacco or alcohol; or had prior human immunodeficiency virus/acquired immune deficiency syndrome diagnosis and lower among those who had seen a dentist the prior year.
conclusionsMedicaid enrollees experienced higher OC/OPC incidence, prevalence, and mortality compared with commercially insured adults. Having seen a dentist within the prior year was associated with a lower risk of OC/OPC diagnosis. IMPACT: Expanding Medicaid dental benefits may allow OC/OPC to be diagnosed at earlier stages through regular dental visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.